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Abstract
Background. The Dialysis Outcomes and Practice Patterns
Study (DOPPS) databasewas used to develop and validate a
practice-related risk score (PRS) based on modifiable prac-
tices to help facilities assess potential areas for improving
patient care.
Methods. Relative risks (RRs) from a multivariable Cox
mortality model, based on observational haemodialysis
(HD) patient data from DOPPS I (1996–2001, seven coun-
tries), were used. The four practices were the percent of
patients with Kt/V ≥1.2, haemoglobin ≥11 g/dl (110 g/l),
albumin≥4.0 g/dl (40g/l) and catheter use, and were signif-
icantly related tomortalitywhenmodelled together.DOPPS
II data (2002–2004, 12 countries) were used to evaluate
the relationship between PRS and mortality risk using Cox
regression.
Results. For facilities in DOPPS I and II, changes in PRS
over time were significantly correlated with changes in the
standardized mortality ratio (SMR). The PRS ranged from
1.0 to 2.1. Overall, the adjusted RR of death was 1.05
per 0.1 points higher PRS (P < 0.0001). For facilities in
both DOPPS I and II (N = 119), a 0.2 decrease in PRS
was associated with a 0.19 decrease in SMR (P = 0.005).
On average, facilities that improved PRS practices showed
significantly reduced mortality over the same time frame.
Conclusions. The PRS assesses modifiable HD practices
that are linked to improved patient survival. Further refine-
ments might lead to improvements in the PRS and will
address regional variations in the PRS/mortality relation-
ship.
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Introduction
Translation of recommendations from clinical practice
guidelines into clinical practice is a challenge, both for
a facility medical director or an individual clinical nephrol-
ogist. The principles of continuous quality improvement
(CQI) are increasingly understood by the renal community,
but barriers prevent widespread utilization of this powerful
methodology. Variability in many aspects of haemodialysis
(HD) care from facility to facility, and from clinician to
clinician, remains an issue, even following the dissemina-
tion of clinical practice guidelines.
Clinical performance measures have evolved as a way
to monitor the implementation of key clinical practice rec-
ommendations. Most modern HD units can report on how
they perform on key indicators such as dialysis dose and
haemoglobin levels. While these indicators show improve-
ment over time and are useful, they are unidimensional
and may not reflect the overall performance of a dialysis
unit [1].
Recently, the DaVita dialysis chain in the United States
developed a dialysis quality index (DQI) that it uses to
promote CQI across its facilities [2,3]. This aggregate in-
dex includes seven variables that are weighted and then
summed to create a 100-point scale. Facilities are tracked
on a quarterly basis, so that both internal and chain-wide
comparisons can be made. Their preliminary data show that
improvements in the DQI are associated with a decrease of
standardized mortality ratios (SMR). Furthermore, the DQI
allows for the identification of poorly performing facilities
that require external assistance with quality improvement.
It also creates a ‘culture of quality’ that serves as a basis for
pride and rewards for a facility’s quality improvement ac-
tivities. The weighting of the formulas was based on expert
opinion. The former Renal Care Group developed a similar
index that was based on 10 clinical quality indicators and
patient satisfaction measures, aggregated to derive a Com-
posite Facility Score (R. Hakim, personal communication).
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The concept and potential usefulness of an aggregate
index like the DQI has considerable merit. However, the
DaVita formula includes the SMR as a minor component of
the index. Given that the index is intended to predict SMR,
the mathematics are flawed if SMR is included in both sides
of the equation. Additionally, an empirical approach to the
weighting of variables would be preferred.
Recently, a group of Canadian nephrologists with an
interest in CQI has been working together to consider
new approaches to CQI, including the development of an
aggregate index for HD facilities. A collaboration with the
Arbor Research Collaborative for Health, who established
the prospective Dialysis Outcomes and Practice Patterns
Study (DOPPS) database, provided a rich resource to
help create and validate an aggregate quality index. This
manuscript describes the process to date that has led to the
development of an outcome-driven aggregate HD quality
index that we call the practice-related risk score (PRS). A
major objective of this was to determine whether we could
correlate improvements in practice with improvements in
patient longevity at the facility level.
Methods
Data sources
DOPPS is a prospective, observational study of adult
HD patients with the present analysis based on data from
seven countries participating in DOPPS I and 12 countries
from DOPPS II. Study inclusion criteria required that
patients were considered by their physicians to require
chronic, maintenance HD (typically at least two to three
HD treatments per week), but allowed for the therapies
of haemodiafiltration and haemofiltration. The first phase
of the study (DOPPS I, 1996–2001) collected data from
308 facilities in France, Germany, Italy, Japan, Spain,
the United Kingdom and the United States. The second
phase (DOPPS II, 2002–2004) of 320 facilities added an
additional five countries to the original seven: Australia,
Belgium, Canada, New Zealand and Sweden. A stratified
random sample of dialysis facilities was selected in each
country, and a census of prevalent HD patients was used
to randomly select 20–40 patients at each facility. Patients
participating in clinical trials were not excluded from
eligibility for DOPPS. Details of the study methodology
have been described previously [4,5].
The patient haemoglobin, serum albumin, pre-and post-
dialysis blood urea nitrogen or blood urea values used in
these analyses were based upon a patient’smost recent value
measured on or before the study entry date. For the majority
of patients, these values were measured within 30 days of
the study enrolment date since all of the laboratorymeasure-
ments are routinely tested for the majority of HD patients.
To minimize the effects of residual renal function on the
relationship between Kt/V and mortality, Kt/V calculations
were restricted to patients having end-stage renal disease
(ESRD) >1 year as only a small fraction of these patients
(<5%) had significant residual renal function after having
ESRD for 1 year or longer. Catheter use was calculated
based upon the type of vascular access a patient was using
on the date of study entry.
Statistical analyses
The PRS was developed based upon several largely modi-
fiable facility HD practices for which The National Kidney
Foundation’s Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines currently exist. A multivariable Cox
mortality model was constructed using a prevalent cross-
section of DOPPS I data (n = 6665) using different levels
of four facility practices. Relative risks from this model
were then used as the score for each level, a method that
used empirical weighting of the relative mortality risk as-
sociated with each level. The best-practice level in each
group served as the reference and therefore had a score
of 1.0 for that practice. The four practices used for de-
veloping the PRS were facility-based percent of patients
with Kt/V ≥1.2, haemoglobin ≥11 g/dl (110 g/l), albumin
≥4.0 g/dl (40 g/l) and catheter use. These factors were se-
lected because each was significantly related to mortality
when included together in the Coxmodel. Differences in the
method of albuminmeasurementwere not considered in this
analysis. Other factors tested in the model but not found to
be significant included serum calcium, serum phosphorus,
calcium–phosphorus product, iPTH, treatment time, short-
ened treatments, multivitamin use and Pneumovax vacci-
nation. Facility-level practices were based on a prevalent
cross-section of patients and restricted to facilities with at
least six patients with available data for each indicator.
The scores for each practice were then multiplied to ob-
tain the PRS. For interpretation, facilities with a PRS of
1.30 have on average a 30% higher risk of mortality rela-
tive to patients in facilities with good practice for all four
facility measures. A facility in the best category for all four
practices would have a score of 1.0.
DOPPS II data (n= 7826)were then used to assess the re-
lationship between the PRS andmortality risk using Cox re-
gression. All models were adjusted for age, sex, black race,
years on dialysis, 14 summary comorbid conditions [coro-
nary artery disease, congestive heart failure, other cardiac
disease, hypertension, cerebrovascular disease, peripheral
vascular disease, diabetes, lung disease, cancer (excluding
skin), HIV/AIDS, gastrointestinal bleeding, neurologic dis-
ease, psychiatric disease and recurrent cellulitis], unit type,
region and accounted for facility clustering.
For those facilities participating in both DOPPS I and
II, an SMR adjusted for the above factors was constructed
to correlate the change in SMR from DOPPS I to II with
the corresponding change in PRS. Expected deaths for the
comorbidity-adjusted SMR were estimated based on a Cox
mortality model using data from both DOPPS I and II.
The PRS was calculated at the start of DOPPS I and the
start of DOPPS II, and the SMR was based on the first
18 months of follow-up from each phase in order to cap-
ture only the time frame nearest to the defined PRS in case
facility practices changed over time. The PRS and SMR
values calculated for facilities participating in DOPPS I
and II were based upon a prevalent cross-section of study
patients who were randomly selected for participation at
the start of DOPPS I and the start of DOPPS II. These
random selections were independent of one another. Thus,
each random selection provides a representative sample of
facility patients in DOPPS I and DOPPS II. Patients could
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only be included in both prevalent cross-sections if receiv-
ing chronic HD in the facility at both time points and if they
were randomly chosen at both time points.
All statistical analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC, USA).
Results
Concepts for development of the PRS
The process of developing the PRS using DOPPS data was
based upon several key concepts: [1] Cox regression mod-
els would be used to estimate the mortality risks associated
with simultaneously achieving certain levels of ‘good
practice’ for various HD practices within a facility and that
the PRS would be calculated from these Cox regression
models by multiplying the relative risks of mortality for
each of the practices within the same model; [2] a facility’s
achievement level for a particular HD practice would be
based upon the percentage of facility patients in a prevalent
cross-section attaining a pre-defined cut-point for ‘good
practice’; [3] cut-points for ‘good practice’ (e.g. percent
of patients with a single pool Kt/V ≥1.2) would be based
upon the current KDOQI guidelines as much as possible;
[4] differences in patient case-mix between facilities would
be accounted for in the mortality models through extensive
adjustment for patient demographics and comorbidities; [5]
a facility’s PRS would be easily interpretable as indicating
the magnitude of additional risk for the facility’s modelled
practices compared to facilities having the best level of
practice in all modelled practice areas; [6] for a facility, an
estimate of mortality risk and level of achievement could be
provided for each facility practice contributing to the PRS,
and; [7] the PRS would be significantly related to mortality
risk when facilities are grouped together by PRS scores;
for this purpose, the construction of the PRS would be per-
formed with DOPPS I data and testing of the PRS/mortality
relationship would be performed with DOPPS II data.
An important feature was an evaluation of a correlation
of changes in PRS over time with changes in mortality
risk.
Facility practices and relationship with mortality risk
Applying the above strategy for developing the PRS, ap-
proximately 10 facility practices were initially investigated
to determine their relationship with mortality risk of facil-
ity patients. Practices and cut-points included the percent of
facility patients with single-pool Kt/V ≥1.2, haemoglobin
≥11 g/dl (110 g/l), serum albumin ≥4.0 g/dl (40 g/l), a
central venous catheter as a vascular access, serum phos-
phorus concentration between 3.5 and 5.5 mg/dl (1.1 and
1.8 mmol/l), serum calcium concentration between 8.4 and
9.5 mg/dl (2.1 and 2.4 mmol/l), calcium–phosphorus prod-
uct, treatment time, shortened treatments, multivitamin use
and Pneumovax vaccination use.
Initially, the relationship between mortality risk and cat-
egories of each facility practice were examined in models
adjusted for patient demographic and comorbid factors but
without adjustment for other facility practices. These anal-
Table 1. Facility measures included in PRS
% patients with Kt/V ≥1.2
% patients with Hgb ≥11 g/dl
% patients with albumin ≥4.0 g/dl
% patients with catheters
Based on a prevalent cross-section of DOPPS I patients. Also tested but
not significant: serum calcium, serum phosphorus, calcium–phosphorus
product, treatment time, shortened treatments, multivitamin use and vac-
cination with Pneumovax.
yses were helpful for (a) indicating whether a given facility
practicewas significantly associatedwithmortality risk and
(b) understanding the shape of the relationship of mortality
risk with different levels of a given facility practice. If the
facility practice was not significantly associated with mor-
tality risk in these analyses, the practice would be excluded
from further consideration for use in constructing the PRS.
On the other hand, facility practices which were signifi-
cantly related to mortality risk in these individual facility
practice models were included together in the final Cox
mortality model which was used to determine the mortal-
ity risks associated with simultaneously achieving different
levels of ‘good practice’ for various HD practices within a
facility. This process resulted in four facility practices dis-
playing a significant relationship withmortality whenmod-
elled simultaneously. The four practices were percent of fa-
cility patients with a single-pool Kt/V ≥1.2, haemoglobin
≥11 g/dl (110 g/l), serum albumin≥4.0 g/dl (40 g/l) and us-
ing central venous catheters as a vascular access (Table 1).
The shape of the relationship of each of these facility prac-
tices with mortality was examined by arbitrarily using five
categories of target achievement over the range from 0 to
100% in increments of 20%. For some of these facility prac-
tices, categories were combined into a single group if the re-
lationship with mortality was similar across the categories
or if the sample size in one particular category was too
small.
For the four facility practices, Table 2 shows the relative
risk of mortality associated with each category of the given
facility practice. Thus, we see for the facility practice of
attaining a single-pool Kt/V ≥1.2 that facilities in which
≤40% of patients achieve this target, a 46% higher risk of
death (RR = 1.46, n = 15 facilities) is seen compared with
the 113 facilities in which 80–100% of patients achieve
this target for dialysis dose. The RRs shown in Table 2 are
based on DOPPS I data, stratified by the seven countries
participating in DOPPS I, and adjusted for the factors as
indicated. Therefore, the RRs shown in Table 2 represent
the average effect across countries.
Calculation of the PRS
The PRS is easily calculated by multiplication of the RRs
corresponding to a facility’s level of practice in each of the
four facility practice areas shown in Table 2. The example
in Table 2 shows a facility having an RR= 1.33 for mortal-
ity risk due to having 40–60% of patients with Kt/V ≥1.2,
RR = 1.00 for having >60% of patients with Hgb ≥11
g/dl (110 g/l), RR = 1.12 for having 10–20% of patients
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Table 2. Calculating PRS based on facility model results
Example
Facility factor N facilities RR∗ death facility
Kt/V >1.2, 0–40% 15 1.46
Kt/V >1.2, 40–60% 49 1.33 a
Kt/V >1.2, 60–80% 99 1.06
Kt/V >1.2, 80–100% 113 1.00
Hgb >11 g/dl, 0–20% 67 1.26
Hgb >11 g/dl, 20–60% 191 1.18
Hgb >11 g/dl, 60–100% 47 1.00 a
Catheter use, 20–100% 61 1.13
Catheter use, 10–20% 63 1.12 a
Catheter use, 0–10% 182 1.00
Albumin >4.0 g/dl, 0–20% 68 1.18
Albumin >4.0 g/dl, 20–40% 87 1.06
Albumin >4.0 g/dl, 40–100% 127 1.00 a
Example facility: PRS score = 1.33 ∗ 1.00 ∗ 1.12 ∗ 1.00 = 1.49.
∗RRs based on the Coxmodel adjusting simultaneously for all four facility
factors and patient age, gender, black race, years with ESRD, 13 summary
comorbid conditions and unit type; analysis was stratified by country, and
accounted for facility clustering effects. The example in the bottom row
shows how the PRS score is calculated for a hypothetical facility having
the categories of HD practice noted with an ‘a’ in the table, and for which
the RRs of death pertaining to these categories are then multiplied by one
another to yield the PRS score.
using a catheter and RR = 1.00 for having >40% of pa-
tients with a serum albumin ≥4.0 g/dl (40 g/l). The PRS
for this facility is obtained by multiplying these four RRs
as 1.33∗1.00∗1.12∗1.00 = 1.49. This PRS of 1.49 can be
readily interpreted that patients within facilities with this
type of practice have a 49% higher mortality risk on aver-
age compared to patients in facilities having the best level
of practice for all four practices areas. This interpretation
is provided from the design feature of basing the PRS upon
RRs that are empirically derived from the simultaneous
facility-level mortality models. Based upon the RRs shown
in Table 2, the PRS calculated in thismanner can range from
a value of 1.0 (facilities with the best levels for all four mea-
sures) to the highest possible value of 2.45 (calculated from
1.46∗1.26∗1.13∗1.18).
Validation of PRS: Relationship between PRS and
mortality risk in DOPPS II data
The PRS was constructed using DOPPS I data collected
in seven countries from 1996 to 2001. The relationship be-
tween PRS and mortality risk was evaluated using DOPPS
II data collected in 12 countries from 2002 to 2004. As
shown in Figure 1, PRS as a continuous variable was
strongly related to mortality risk in the DOPPS II patient
sample, with a 5% higher mortality risk observed for every
0.1 point higher PRS score (P < 0.0001). For these analy-
ses, 282 facilities in DOPPS II displayed PRS ranging from
a low value of 1.0 to a high value of 2.1. When these facility
PRS were categorized into quartiles of the score, mortality
risk was seen to be higher with each higher quartile of the
PRS score, with a plateau in the two highest categories.
Since the PRS is composed of multiple facility practices
with varying contributions of each practice to the score,
it can be expected that the relationship between PRS and
mortality risk will not necessarily be linear across the range
of PRS scores. Patients dialyzing in facilities with the high-
est PRS quartile (PRS from 1.42 to 2.1) had a 41% higher
mortality risk on average (P < 0.0001) compared with
patients treated in facilities having a PRS of 1.0–1.19 (the
lowest PRS quartile). All of these analyses were adjusted
for patient demographics, comorbidities, unit type and were
stratified by country. TheDOPPS I study design allowed for
the stability of facility PRS to be examined. In comparing
the PRS score for a facility at the time of study entry and
1 year later, the median percent change in facility PRS over
this 1-year time periodwas 0.0% (25th percentile=−3.7%,
75th percentile = 6.4%), indicating the relative stable na-
ture of the PRS score for many facilities over this period of
analysis.
A sensitivity analysis was performed to determine the
relationship of PRS with mortality by three regions in the
DOPPS: North America, Europe+Australia/New Zealand
and Japan. The PRS was most strongly related to mortality
in North America with a 6% higher mortality risk for every
0.1 higher PRS (P < 0.0001). The PRS/mortality relation-
ship was slightly weaker (RR = 1.05 per 0.1 higher PRS,
P= 0.008) in the Europe+Australia/New Zealand sample.
However, the composition of the PRS does not appear to be
informative regarding mortality risk in Japan (RR = 0.98
per 0.1 higher PRS, P = 0.62).
Does a change in facility PRS over time correlate with
temporal changes in facility mortality risk?
A PRS may serve as an instrument for dialysis facilities in
gauging improvements in certain HD practices over time.
Longitudinal DOPPS data provide the opportunity for in-
vestigating whether changes in a facility’s PRS over time
are significantly related to mortality risk over the same
time period. Thus, we hypothesized that if dialysis facilities
improved their PRS by improving dialysis dose, anaemia
management, vascular access use and/or nutritional status
of their patients from DOPPS I to II, while keeping all else
constant, then would show a significantly reducedmortality
risk over the time period.
Analyses had to be restricted to the 124 dialysis units
participating in both DOPPS I and II. As indicated by the
schematic diagram in Figure 2, for each facility a PRS1
was calculated based upon a prevalent cross-section of pa-
tients at the start of DOPPS I, and a PRS2 was calculated
based upon a prevalent cross-section of patients at the start
of DOPPS II. The PRS corresponds to the difference in
PRS2 − PRS1. In order to assess each facility’s mortality
risk in DOPPS I versus DOPPS II, an SMR was calculated
for each facility for the first 1.5 years of the study follow-up
in DOPPS I and DOPPS II, yielding an SMR1 and SMR2,
respectively. The SMR corresponds to the difference in
SMR2-SMR1. Approximately 60% of facilities improved
their PRS from DOPPS I to DOPPS II while the remain-
ing facilities showed either a stable PRS or a decline in
performance.
Based on regression analysis, Figure 3 shows that a
0.2-point decrease in the facility PRS from DOPPS I to
II was significantly associated with a 0.19-point decrease
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Fig. 1. Adjusted relative risk of death in DOPPS II HD patients, by quartiles of the practice-related risk score (PRS). The PRS was calculated for each
facility participating in DOPPS II based upon the RR of death indicated in Table 2 for different practice levels, and the percentages of facility patients
in DOPPS II with a Kt/V ≥1.2, Hgb ≥11 g/dl, serum albumin ≥4.0 g/dl and using a catheter for vascular access. These percentages were calculated
from the prevalent cross-section of study patients treated in the facility at the time of initiating DOPPS II data collection. Each facility patient in this
prevalent cross-section was assigned the facility’s PRS value. The relationship between patient mortality risk and PRS quartile was analysed using Cox
regression models, adjusting for age, gender, black versus non-black race, years with end-stage renal disease, 13 summary comorbid conditions and unit
type (n = 7826). Models were stratified by country, and accounted for facility clustering effects. The inset indicates the relationship between mortality
risk and PRS as a continuous variable.
Fig. 2. Design of the facility-based delta–delta analysis method. Separate
PRS values were calculated at the beginning of DOPPS I (PRS1) and
DOPPS II (PRS2) for each facility. A facility’s PRS value at each time
point was calculated as described in Table 2 based upon a prevalent cross-
section of patients in the facility at the given time point. The delta PRSwas
calculated as the difference of PRS2 − PRS1. Similarly, for each facility
an SMR was calculated for the 1.5 years of the study follow-up after the
beginning of each study phase to provide an SMR1 for DOPPS I and an
SMR2 for DOPPS II. The delta SMR was calculated as the difference of
SMR2− SMR1. Linear regression analysis was then applied to determine
the relationship between SMR and PRS. SMRs were adjusted for
numerous patient characteristics and comorbidities as described in the
Methods section.
in the facility SMR (P = 0.005). This is equivalent to a
decline in facility SMR from 1.0 to 0.81 or as a reduction
from 18 to 15 annual deaths in a facility treating 100 chronic
HD patients. Analyses using a shorter mortality follow-up
time of 1 year showed a very similar relationship between
PRS and SMR as seen in the models using 1.5 years of
mortality follow-up time, although with less precision due
to the substantially shorter follow-up time.
A sensitivity analysis was performed to determine if the
relationship between facilityPRS and facilitySMR dif-
fered if facilities with a very low mortality risk in DOPPS I
(≤8 deaths per 100 patient-years) were excluded. This re-
stricted analysis of 80 facilities indicated an even stronger
Fig. 3. Delta–delta analysis: average change in SMR per 0.2 point de-
crease in PRS from DOPPS I to DOPPS II. Linear regression was used to
examine the relationship between PRS and SMR. Data were available
from 124 facilities participating in both DOPPS I and II for which PRS
and SMR could be calculated. A sensitivity analysis was performed to
examine the relationship between PRS and SMR when restricted to
facilities having a crude death rate ≥8% in DOPPS I (n = 80).
relationship between PRS and SMR with a 0.2-point
decrease in the facility PRS from DOPPS I to II being
associated with a 0.22-point decrease in the facility SMR
(P = 0.002) (e.g. 22 versus 17 annual deaths per 100 pa-
tients). Overall, these ‘delta–delta’ results indicate the abil-
ity of the PRS to serve as an aggregate index of improve-
ments in HD practices, which are significantly related to
improvements in patient survival.
Discussion
Results from a prospective, observational study like the
DOPPS are considered to be hypothesis generating and
often raise questions that are best answered by randomized
controlled trials. One limitation of observational studies
based on patient-level data is the existence of unmeasured
confounding whichmay play an integral role in the relation-
ship seen between a patient-related factor and an outcome.
By adjusting analyses for many potential confounding
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elements, the risk that the observed relationship between
the measured factor and an outcome is due to confounding
can be reduced, but not completely eliminated. However,
an important methodology upon which the DOPPS study
design is based is to analyse outcomes in relationship
to facility practices rather than patient-level factors as a
means to further reduce the confounding by indication that
is inherent in patient-level analyses, and thereby provide a
greater opportunity to observe the true relationship between
a practice and outcome. The present study shows a strong
association of facility practices with facility mortality risk
with full adjustment for case-mix as a refined SMR.
Furthermore, an additional methodology used in the
present work, which we refer to as the facility-based delta–
delta analysis, serves as another important tool for further
reducing confounding. The correlation of facility-level
changes in practice (PRS) with facility-level changes
in outcomes (SMR), the delta–delta analysis is a major
validation of the DOPPS approach since it shows that
positive interventions to improve several intermediate
outcomes are associated with improvements in SMR.
This finding brings us closer to suggesting causality, as it
simulates a randomized controlled trial of an experiment
in which some facilities implement a change in practice
whereas other facilities do not and then this change in
practice is correlated with changes in facility outcomes
such as SMR. Since each facility serves as its own control,
this methodology provides a powerful means within an
observational study setting to account for patient-level
confounding, particularly if the time period is relatively
short over which these facility practice changes are
monitored.
It is possible that themechanisms that lead from reducing
PRS scores over time to better hard outcomes are both
direct and indirect. In other words, some of the benefit may
accrue directly from improving performance that focuses
directly on guideline targets. In addition, some of the
benefit may relate to other improvements in care that are
made when a culture of quality and a systematic approach
to quality improvement is implemented in HD facilities.
The present study design does not allow for quantification
of the relative contribution of these direct and indirect
effects.
The PRS is intentionally based upon clinically important
and modifiable practice patterns. Nonetheless, there is a
view that both low haemoglobin and low albumin levels
reflect serious illness with a poor prognosis, and that efforts
to increase them in isolation may not lead to the expected
improvement in prognosis. Certainly, for haemoglobin,
there are easily implemented, clinical manoeuvres that can
be applied to achieve partial correction. However, those
who do not respond and who have a high ESA/Hb ratio
remain at high risk of mortality [6].
The powerful negative predictive effect of albumin on
prognosis in HD patients has been recognized since 1992
[7]. Despite this, very little research effort has gone into
developing robust clinical approaches to albumin correc-
tion. Indeed, because serum albumin is inherently difficult
to change with current treatment paradigms in HD, we have
empirically tried to remove it from the PRS formula. How-
ever, a three-variable model without albumin was not as ro-
bust. Similarly, the replacement of the variable of albumin
with other variables such as serum phosphate, serum cal-
cium, calcium–phosphorus product, iPTH, treatment time
and skipped treatments was associated with a worse per-
formance for the score. Furthermore, models that used five
and six variables, models with adjustments of the selected
optimal ranges and models with weighting of variables also
did not improve the score. Although higher serum calcium–
phosphorus product levels and shorter treatment time are
known to be associated with higher HD patient mortality
risks, the lack of a significant contribution of these factors
at the facility level to the PRS in the current work may be
due to (a) part of their effects explained by other treatment
practices already included in the PRS or (b) a narrower
range of practice variability across facilities coupled with
a small mortality effect size across this range of practice
variability. While we recognize that inclusion of albumin in
the PRS may be viewed by some as a limitation, we hope
that these results will stimulate new research initiatives to
achieve better albumin results. These might include longer
HD treatment times and/or daily HD. We suggest that ap-
proaches involving a direct focus on the manipulation of al-
bumin, along with indirect efforts to correct the underlying
inflammation and other factors that cause the low albumin
(and low haemoglobin in ESA resistant patients), must be
explored.
One caveat when applying the PRS within a given facil-
ity is that mortality associations are averaged across many
DOPPS units and may not reflect the mortality experience
at a particular facility. This study clearly suggests that no
matter what baseline demographics, comorbidity or SMR
are observed in a given facility, an improvement in PRS
is likely to be associated with an improvement in patient
survival within that facility.
The lack of applicability of the PRS among Japanese pa-
tients is not well understood. It may be due to the fact that
catheter use is low (<5%) in Japan in nearly all dialysis
units, and so in Japan there is little variability regarding
this component of the PRS. Less variation is also seen in
the haemoglobin component, with a consistently lower per-
centage of patients achieving haemoglobin levels of >11
g/dl (110 g/l) compared to other countries. Further investi-
gations are needed to understand these regional variations
in the relationship between PRS andmortality for future en-
hancements of the PRS. Sensitivity analyses indicate that
overall results do not vary greatly when Japan is excluded
from the analysis. Additionally, the delta–delta relationship
holds for Japan, though the relationship is only marginally
significant (0.09). This may be due to the smaller sample
size of the country-specific analysis.
Wolfe et al. have previously applied this facility-based
delta–delta analysis methodology to a US national database
of 2858 facilities, to show that changes in adherence to
guidelines for haemoglobin and dialysis dose over a 4-year
time period was associated with changes in mortality risk
[1]. Facilities in the highest tertiles of improvement of both
urea reduction ratio and haematocrit ≥33% had the biggest
improvement in mortality outcomes. In other words, simul-
taneous changes in two key practices were associated, each
independently, with an impact on survival. This current
study is important because it confirms those observations
A PRS for haemodialysis facilities 3233
in a different, international database, and it extends them to
include other practice patterns. Several patient-based anal-
yses agree with an association between guideline targets
achieved and patient survival, but such studies are more
prone to confounding than facility-based analyses [8–11].
The need for an aggregate index has been recognized by
the hospital sector for many years. Hospitals track not only
key clinical performance measures, but also include patient
and staff satisfaction and financial indicators in what has
become known as a hospital-balanced scorecard. The PRS
can be considered a step along a similar pathway towards
a broader and more comprehensive attempt to describe the
quality of a single or group of HD facilities. In 2006, there
were no dialysis-specific, standardized, industry-wide
instruments to measure patient and staff satisfaction. We
encourage the development of these tools, and we antici-
pate that the PRS might be modified to include them in the
future.
Some facilities treat older or sicker patients. For this
reason, comparisons of PRS must include many other stan-
dard indicators such as age, diabetes and other factors to
allow comparisons of practices. At present, we recommend
that the use of the PRS be limited to internal facility pur-
poses, at least until further validation and implementation
studies are completed. Furthermore, this work supports the
achievement of KDOQI targets and should not be extrap-
olated to suggest that an increased benefit might accrue if
KDOQI targets were exceeded. Finally, DOPPS analyses
are based upon results for HD patients only and therefore
are not generalizable to peritoneal dialysis patients.
In conclusion, the PRS assesses four key modifiable HD
practices that are linked to improved patient survival. The
mathematical calculations are simple and the data required
are likely to be available in most HD facilities. On aver-
age, facilities that improved their PRS practices over time
showed significantly reduced mortality over the same time.
The PRS may be a useful aggregate quality index for HD
facilities. It may catalyze an enhanced culture of quality
within or across facilities. However, this PRS should be
considered to be only the initial version since development
and perfection of an aggregate HD quality index will be an
iterative process. Further refinements are ongoing to im-
prove the PRS, and to address regional variations in the
PRS/mortality relationship.
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